Vivani’s Board Overhaul Signals High-Stakes Push into GLP-1 Market

ALAMEDA, CA – June 26, 2026 – In the world of clinical-stage biopharmaceuticals, board appointments are rarely just routine personnel changes. They are tectonic signals, telegraphed moves in a high-stakes chess match against time, capital, and biology. Vivani Medical’s announcement today—appointing financial veteran August J. Moretti to its board while bidding farewell to long-tenured director Dr. Dean Baker—is a case in point. It’s a calculated maneuver that speaks volumes about the company's transition from a foundational, technology-focused entity into a disciplined organization bracing for the immense financial and operational pressures of late-stage clinical development and potential commercialization.

Vivani is placing a massive bet on its proprietary NanoPortal™ technology, a miniature subdermal implant designed to deliver drugs like semaglutide for months at a time. As the company prepares to initiate its pivotal SLIM-1 clinical trial for its lead candidate, NPM-139, the appointment of Moretti is a clear signal that the firm is reinforcing its financial and strategic architecture for the marathon ahead. This isn't just about keeping the lights on; it's about building a fortress capable of challenging the giants of the pharmaceutical world.

Fortifying the Financial Front Lines

August Moretti is not a newcomer to the brutal realities of biopharmaceutical finance. His resume reads like a tour of the sector's most challenging phases. As the former CFO of companies like 4D Molecular Therapeutics, Assertio Therapeutics, and Alexza Pharmaceuticals, he has navigated the complex landscapes of early-stage development, public financings, mergers, and product commercialization. His experience at Alexza is particularly noteworthy, having guided the company through its IPO and the launch of its lead product. This is precisely the kind of battle-tested expertise a company like Vivani needs as it moves from promising preclinical data to the unforgiving scrutiny of human trials and public markets.

“His expertise will be instrumental as we advance our lead semaglutide implant, NPM-139, through clinical-stage development,” said Gregg Williams, Vivani’s Chairman of the Board. The term “instrumental” is hardly an overstatement. According to its recent filings, the company has a cash runway projected to last through the first half of 2027. While a significant runway, the costs of advancing a drug through Phase 1, Phase 2, and the monumentally expensive Phase 3 trials can deplete even healthy coffers with alarming speed. Moretti, who will immediately chair the Audit Committee, is being brought in to ensure every dollar is maximized and to architect the financial strategy for the inevitable future capital raises required to see NPM-139 through to a potential FDA submission.

His appointment is a move to build investor confidence, signaling that a seasoned financial steward is now co-piloting the ship. In an industry where promising science often withers on the vine for lack of capital, installing a director with a proven track record in fundraising and financial governance is a foundational act of structural reinforcement.

The High-Stakes Gamble on Adherence

The reason for this financial fortification is the sheer scale of the opportunity—and the competition. Vivani is targeting the GLP-1 market, a therapeutic space for obesity and type-2 diabetes that is not just growing but exploding, with market projections soaring past $100 billion within the next decade. This arena is currently dominated by two titans: Novo Nordisk, with its blockbuster products Ozempic and Wegovy, and Eli Lilly, with its formidable Mounjaro and Zepbound. These are not just drugs; they are cultural phenomena, backed by marketing budgets that dwarf the entire market capitalization of many smaller biotech firms.

Vivani’s strategy is not to compete on marketing muscle but on technological differentiation. The core problem with current GLP-1 therapies, despite their efficacy, is adherence. Patients must commit to daily pills or weekly self-injections, a routine that a staggering number of people fail to maintain over the long term. This is where Vivani’s NanoPortal™ implant aims to carve out its niche. The company is developing a system that could potentially deliver a near-constant, steady dose of semaglutide for six months or even a full year from a single, reversible subdermal implant.

This “set it and forget it” approach directly addresses the structural weakness of the current treatment paradigm: human behavior. By guaranteeing adherence, the implant could help patients realize the full potential benefit of the medication while potentially smoothing out the side effects associated with the peak-and-trough drug levels of intermittent dosing. Preclinical data has been promising, showing significant weight loss maintained over six months with a single implant. The upcoming SLIM-1 trial, which will compare a low-dose NPM-139 against weekly injections, is the first critical test of whether this promise translates to humans. A positive result would be a major de-risking event, but the path is long and fraught with peril.

A Changing of the Guard

Concurrent with Moretti’s arrival is the retirement of Dr. Dean Baker, a move that marks the end of a significant chapter for Vivani. Dr. Baker was a pivotal figure, described by the company as having provided “critical guidance” during the 2022 reverse merger between Nano Precision Medical and Second Sight Medical Products—the very transaction that created the modern Vivani. That merger was a radical pivot, shifting the company's focus from Second Sight's visual prosthetics to Nano Precision's drug delivery platform. Dr. Baker, with his deep operational and technical insights, was an architect of that transition.

His departure signifies that the integration phase is complete. The foundational structure he helped build is now in place, and the company is shifting its focus from internal transformation to external execution. “On behalf of the entire board, I want to thank Dean for his dedicated service and invaluable contributions to Vivani,” Williams added, acknowledging the importance of his tenure. Dr. Baker’s retirement is not a sign of instability but rather a natural evolution, making way for a new set of skills tailored for the next leg of the journey.

This transition from a board member who guided a merger to one who has managed commercial launches and public company finances encapsulates Vivani’s own strategic maturation. The company is evolving from a story about technological integration to one about clinical execution and commercial ambition, a systemic shift that requires a different kind of leadership at the highest level.